![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Scottish Generic Firm Files Patent Challenge on Sanofi-Aventis' Plavix
Scottish Generic Firm Files Patent Challenge on Sanofi-Aventis' Plavix
French drugmaker sanofi-aventis is facing yet another patent challenge -- this time in Europe -- to its top-selling antistroke drug Plavix.
Aircoat, a Scottish generic firm, has challenged sanofi-aventis' Plavix (clopidogrel bisulfate) patent in a Scottish Court. The UK patent was issued from sanofi-aventis' European patent, the company said.
"Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent," the company added.
Sanofi-aventis is already facing two patent suits against Plavix in the U.S. Dr. Reddy's and Apotex both filed abbreviated new drug applications in 2002 to market a Plavix equivalent. Sanofi-aventis has filed suit in federal court to block the U.S. patent challenges. The company announced recently that the U.S. case is set to go to trial March 4.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct